1-tert-butyl 2-methyl (2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1,2-pyrrolidinedicarboxylate | 121148-04-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-tert-butyl 2-methyl (2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1,2-pyrrolidinedicarboxylate
• 英文别名: (2S,4R)-1-t-butoxycarbonyl-4-(4-chlorophenylsulfonylamino)-2-methoxycarbonylpyrrolidine；1-O-tert-butyl 2-O-methyl (2S,4R)-4-[(4-chlorophenyl)sulfonylamino]pyrrolidine-1,2-dicarboxylate
• CAS: 121148-04-7
• 化学式: C₁₇H₂₃ClN₂O₆S
• 分子量: 418.898
• InChiKey: NPRYWUNWMAFSMX-OCCSQVGLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  1-tert-butyl 2-methyl (2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1,2-pyrrolidinedicarboxylate 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以65.9%的产率得到tert-butyl (2S,4R)-2-formyl-4-(((4-chlorophenyl)sulfonyl)amino)pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and Biological Activity of 1-Phenylsulfonyl-4-Phenylsulfonylaminopyrrolidine Derivatives as Thromboxane A 2 Receptor Antagonists

  摘要：

  The synthesis and biological activity of novel 1-phenylsulfonyl-4- phenylsulfonylaminopyrrolidine analogues are described. All compounds were produced through modification of the substituent formally corresponding to the 1,3-dioxane ring system and the omega-octenol side chain of thromboxane A(2) (TXA(2)), in reference to the structure of Daltroban. Several compounds were found to be potent TXA(2) receptor antagonists. Compound 51a was the most effective inhibitor of 9.11-epoxymethano PGH(2) (U-46619)-induced rat aortic strip contraction (IC50 = 0.48 nM). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00397-2
• 作为产物：
  描述：

  L-羟基脯氨酸 在 palladium on activated charcoal 氯化亚砜 、 sodium azide 、 氢气 、 potassium carbonate 、 三乙胺 作用下， 以 吡啶 、 甲醇 、 二氯甲烷 、 二甲基亚砜 为溶剂， 90.0 ℃ 、303.98 kPa 条件下， 反应 26.0h， 生成 1-tert-butyl 2-methyl (2S,4R)-4-(((4-chlorophenyl)sulfonyl)amino)-1,2-pyrrolidinedicarboxylate
  参考文献：
  名称：

  Synthesis and Biological Activity of 1-Phenylsulfonyl-4-Phenylsulfonylaminopyrrolidine Derivatives as Thromboxane A 2 Receptor Antagonists

  摘要：

  The synthesis and biological activity of novel 1-phenylsulfonyl-4- phenylsulfonylaminopyrrolidine analogues are described. All compounds were produced through modification of the substituent formally corresponding to the 1,3-dioxane ring system and the omega-octenol side chain of thromboxane A(2) (TXA(2)), in reference to the structure of Daltroban. Several compounds were found to be potent TXA(2) receptor antagonists. Compound 51a was the most effective inhibitor of 9.11-epoxymethano PGH(2) (U-46619)-induced rat aortic strip contraction (IC50 = 0.48 nM). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00397-2

文献信息

• Pyrrolidine derivatives as antiasthmatics
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04916152A1

  公开（公告）日：1990-04-10

  The invention relates to novel compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkoxycarbonyl, phenylsulfonyl, phenylsulfonyl substituted with 1 to 3 substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, mono (or di or tri)halo(lower)alkyl and lower alkyl, phenylcarbamoyl, lower alkylsulfonyl, benzoyl or thienylsulfonyl; R.sup.2 is phenylsulfonyl or phenylsulfonyl substituted with 1 to 3 substituent(s) selected from the group consisting of halogen, lower alkyl, lower alkoxy and mono(or di or tri)halo(lower)alkyl, R.sup.3 is carboxy(lower)alkyl, lower alkyl substituted with carboxy and 1 to 3 halogen atom(s), esterified carboxy(lower)alkyl, carbamoyl(lower)alkyl, lower alkylsulfonylcarbamoyl(lower)alkyl, phenylsulfonylcarbamoyl(lower)alkyl, carboxyphenyl, esterified carboxyphenyl, carboxy, esterified carboxy, hydroxy(lower)alkyl, sulfino(lower)alkyl, phosphono(lower)alkyl, di(lower)alkoxyphosphoryl(lower)alkyl or halo(lower)alkyl, R.sup.7 is hydrogen or lower alkyl, and A is ##STR2## in which R.sup.8 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt thereof, useful as therapeutic agents for thrombosis, asthma and nephritis.

  该发明涉及以下结构的新化合物：##STR1## 其中R.sup.1为氢、较低的烷氧羰基、苯基磺酰基、苯基磺酰基，其上带有1至3个取代基，所述取代基选自卤素、硝基、较低烷氧基、单(或双或三)卤代(较低)烷基和较低烷基、苯基氨基甲酰基、较低烷基磺酰基、苯甲酰基或噻吩基磺酰基；R.sup.2为苯基磺酰基或苯基磺酰基，其上带有1至3个取代基，所述取代基选自卤素、较低烷基、较低烷氧基和单(或双或三)卤代(较低)烷基，R.sup.3为羧基(较低)烷基、较低烷基，其上带有羧基和1至3个卤原子，酯化的羧基(较低)烷基、氨基甲酰基(较低)烷基、较低烷基磺酰基氨基甲酰基(较低)烷基、苯基磺酰基氨基甲酰基(较低)烷基、羧基苯基、酯化的羧基苯基、羧基、酯化的羧基、羟基(较低)烷基、磺基(较低)烷基、磷酸(较低)烷基、二(较低)烷氧基磷酰(较低)烷基或卤代(较低)烷基，R.sup.7为氢或较低烷基，A为##STR2## 其中R.sup.8为氢或较低烷基，或其药学上可接受的盐，用作治疗血栓、哮喘和肾炎的治疗剂。
• Pyrrolidine derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05264453A1

  公开（公告）日：1993-11-23

  This invention relates to pyrrolidine derivatives and pharmaceutically acceptable salts thereof of the structure ##STR1## where R.sup.1, R.sup.2, and R.sup.3 are as defined herein. These compounds are for pharmaceutical use in treating thrombotic diseases, asthma or nephritis.

  本发明涉及一种吡咯烷衍生物及其药学上可接受的盐，其结构为## STR1 ##其中R.sup.1，R.sup.2和R.sup.3如本文所定义。这些化合物用于药物治疗血栓性疾病，哮喘或肾炎。
• SEHTOI, XIROYUKI;XIRAI, XIDEHO;MARUSAVA, XIROSI;KURODA, AKIO;TANAKA, JOSI+
  作者：SEHTOI, XIROYUKI、XIRAI, XIDEHO、MARUSAVA, XIROSI、KURODA, AKIO、TANAKA, JOSI+

  DOI：——

  日期：——
• US4916152A
  申请人：——

  公开号：US4916152A

  公开（公告）日：1990-04-10
• US5130323A
  申请人：——

  公开号：US5130323A

  公开（公告）日：1992-07-14